Explore the Potential with AI-Driven Innovation
The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
We utilise our cutting-edge, exclusive workflow to develop focused libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
It includes comprehensive molecular simulations of the catalytic and allosteric binding pockets and the ensemble virtual screening accounting for their conformational mobility. In the case of designing modulators, the structural changes induced by reaction intermediates are taken into account to leverage activity and selectivity.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
Q14123
UPID:
PDE1C_HUMAN
Alternative names:
Hcam3
Alternative UPACC:
Q14123; B3KPC6; E9PE92; Q14124; Q8NB10
Background:
Dual specificity calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1C, also known as Hcam3, plays a pivotal role in cellular processes by modulating the amplitude and duration of cAMP and cGMP signals. These second messengers are crucial for physiological functions, including odorant-induced action potential generation in sensory cilia and smooth muscle cell proliferation. The protein also influences the stability of growth factor receptors like PDGFRB.
Therapeutic significance:
The association of Hcam3 with autosomal dominant deafness, 74, underscores its clinical relevance. This condition, characterized by progressive hearing loss starting in the third decade, is linked to gene variants affecting Hcam3. Understanding Hcam3's role could unveil new therapeutic avenues for treating this form of deafness.